Myo-Inositol Consensus: New Recommendations For PCOS Skin Manifestations

An international Delphi consensus group has formally established new recommendations regarding the use of myo-inositol to treat cutaneous, or skin-related, manifestations of Polycystic Ovary Syndrome (PCOS). This clinical consensus aims to provide dermatologists and endocrinologists with a standardized framework for integrating this supplement into their therapeutic strategies for managing skin conditions associated with the endocrine disorder.

The shift toward utilizing myo-inositol is rooted in its role in improving insulin sensitivity, a key factor that often exacerbates the hormonal imbalances leading to PCOS symptoms such as acne and hirsutism. By addressing the metabolic root of these skin concerns, clinicians can offer a more holistic treatment approach. The international group’s efforts serve to harmonize global clinical practices, ensuring that patients receive evidence-informed advice when considering supplemental treatments for their condition.

As these recommendations begin to influence dermatology practice, the focus remains on consistent application and patient selection. While myo-inositol is increasingly viewed as a supportive agent for endocrine health, experts emphasize the need for continued monitoring and long-term research to validate its efficacy across diverse patient demographics. For patients and practitioners alike, this consensus establishes a clearer baseline for navigating treatment options for PCOS-related skin concerns.